TY - JOUR AU - Kaiser, J. PY - 2015 DA - 2015// TI - Senate panel approves $2 billion raise for NIH in 2016 JO - Sci Mag ID - Kaiser2015 ER - TY - JOUR AU - Collins, F. S. AU - Varmus, H. PY - 2015 DA - 2015// TI - A new initiative on precision medicine JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMp1500523 DO - 10.1056/NEJMp1500523 ID - Collins2015 ER - TY - JOUR AU - Rogers, J. F. AU - Nafziger, A. N. AU - Bertino, J. S. PY - 2002 DA - 2002// TI - Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs JO - Am J Med VL - 113 UR - https://doi.org/10.1016/S0002-9343(02)01363-3 DO - 10.1016/S0002-9343(02)01363-3 ID - Rogers2002 ER - TY - JOUR AU - Evans, W. E. AU - Relling, M. V. PY - 2004 DA - 2004// TI - Moving towards individualized medicine with pharmacogenomics JO - Nature VL - 429 UR - https://doi.org/10.1038/nature02626 DO - 10.1038/nature02626 ID - Evans2004 ER - TY - JOUR AU - Wang, W. Y. AU - Barratt, B. J. AU - Clayton, D. G. AU - Todd, J. A. PY - 2005 DA - 2005// TI - Genome-wide association studies: theoretical and practical concerns JO - Nat Rev Genet VL - 6 UR - https://doi.org/10.1038/nrg1522 DO - 10.1038/nrg1522 ID - Wang2005 ER - TY - JOUR AU - Welsh, M. AU - Mangravite, L. AU - Medina, M. W. AU - Tantisira, K. AU - Zhang, W. AU - Huang, R. S. AU - McLeod, H. AU - Dolan, M. E. PY - 2009 DA - 2009// TI - Pharmacogenomic discovery using cell-based models JO - Pharmacol Rev VL - 61 UR - https://doi.org/10.1124/pr.109.001461 DO - 10.1124/pr.109.001461 ID - Welsh2009 ER - TY - JOUR AU - Penny, M. A. AU - McHale, D. PY - 2005 DA - 2005// TI - Pharmacogenomics and the drug discovery pipeline: when should it be implemented? JO - Am J Pharmacogenomics VL - 5 UR - https://doi.org/10.2165/00129785-200505010-00005 DO - 10.2165/00129785-200505010-00005 ID - Penny2005 ER - TY - JOUR AU - Wheeler, H. E. AU - Dolan, M. E. PY - 2012 DA - 2012// TI - Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation JO - Pharmacogenomics VL - 13 UR - https://doi.org/10.2217/pgs.11.121 DO - 10.2217/pgs.11.121 ID - Wheeler2012 ER - TY - JOUR AU - Niu, N. AU - Wang, L. PY - 2015 DA - 2015// TI - In vitro human cell line models to predict clinical response to anticancer drugs JO - Pharmacogenomics VL - 16 UR - https://doi.org/10.2217/pgs.14.170 DO - 10.2217/pgs.14.170 ID - Niu2015 ER - TY - JOUR PY - 2008 DA - 2008// TI - SLCO1B1 variants and statin-induced myopathy—a genomewide study JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0801936 DO - 10.1056/NEJMoa0801936 ID - ref10 ER - TY - JOUR AU - Li, J. H. AU - Joy, S. V. AU - Haga, S. B. AU - Orlando, L. A. AU - Kraus, W. E. AU - Ginsburg, G. S. AU - Voora, D. PY - 2014 DA - 2014// TI - Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients JO - J Pers Med VL - 4 UR - https://doi.org/10.3390/jpm4020147 DO - 10.3390/jpm4020147 ID - Li2014 ER - TY - JOUR AU - Tardif, J. C. AU - Rheaume, E. AU - Lemieux Perreault, L. P. AU - Gregoire, J. C. AU - Feroz Zada, Y. AU - Asselin, G. PY - 2015 DA - 2015// TI - Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib JO - Circ Cardiovasc Genet VL - 8 UR - https://doi.org/10.1161/CIRCGENETICS.114.000663 DO - 10.1161/CIRCGENETICS.114.000663 ID - Tardif2015 ER - TY - JOUR AU - Hu, M. AU - Tomlinson, B. PY - 2013 DA - 2013// TI - Pharmacogenomics of lipid-lowering therapies JO - Pharmacogenomics VL - 14 UR - https://doi.org/10.2217/pgs.13.71 DO - 10.2217/pgs.13.71 ID - Hu2013 ER - TY - JOUR AU - Aslibekyan, S. AU - Straka, R. J. AU - Irvin, M. R. AU - Claas, S. A. AU - Arnett, D. K. PY - 2013 DA - 2013// TI - Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies JO - Expert Rev Cardiovasc Ther VL - 11 UR - https://doi.org/10.1586/erc.12.134 DO - 10.1586/erc.12.134 ID - Aslibekyan2013 ER - TY - JOUR AU - Ji, Y. AU - Schaid, D. J. AU - Desta, Z. AU - Kubo, M. AU - Batzler, A. J. AU - Snyder, K. PY - 2014 DA - 2014// TI - Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations JO - Br J Clin Pharmacol VL - 78 UR - https://doi.org/10.1111/bcp.12348 DO - 10.1111/bcp.12348 ID - Ji2014 ER - TY - JOUR AU - Lin, E. AU - Lane, H. Y. PY - 2015 DA - 2015// TI - Genome-wide association studies in pharmacogenomics of antidepressants JO - Pharmacogenomics VL - 16 UR - https://doi.org/10.2217/pgs.15.5 DO - 10.2217/pgs.15.5 ID - Lin2015 ER - TY - JOUR AU - Wheeler, H. E. AU - Maitland, M. L. AU - Dolan, M. E. AU - Cox, N. J. AU - Ratain, M. J. PY - 2013 DA - 2013// TI - Cancer pharmacogenomics: strategies and challenges JO - Nat Rev Genet VL - 14 UR - https://doi.org/10.1038/nrg3352 DO - 10.1038/nrg3352 ID - Wheeler2013 ER - TY - JOUR AU - McLeod, H. L. PY - 2013 DA - 2013// TI - Cancer pharmacogenomics: early promise, but concerted effort needed JO - Science VL - 339 UR - https://doi.org/10.1126/science.1234139 DO - 10.1126/science.1234139 ID - McLeod2013 ER - TY - JOUR AU - Schroth, W. AU - Antoniadou, L. AU - Fritz, P. AU - Schwab, M. AU - Muerdter, T. AU - Zanger, U. M. PY - 2007 DA - 2007// TI - Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2007.12.2705 DO - 10.1200/JCO.2007.12.2705 ID - Schroth2007 ER - TY - JOUR AU - Cote, J. F. AU - Kirzin, S. AU - Kramar, A. AU - Mosnier, J. F. AU - Diebold, M. D. AU - Soubeyran, I. AU - Thirouard, A. S. AU - Selves, J. AU - Laurent-Puig, P. AU - Ychou, M. PY - 2007 DA - 2007// TI - UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-2290 DO - 10.1158/1078-0432.CCR-06-2290 ID - Cote2007 ER - TY - JOUR AU - Innocenti, F. AU - Schilsky, R. L. AU - Ramirez, J. AU - Janisch, L. AU - Undevia, S. AU - House, L. K. PY - 2014 DA - 2014// TI - Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2014.55.2307 DO - 10.1200/JCO.2014.55.2307 ID - Innocenti2014 ER - TY - JOUR AU - Brauch, H. AU - Schwab, M. PY - 2014 DA - 2014// TI - Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer JO - Br J Clin Pharmacol VL - 77 UR - https://doi.org/10.1111/bcp.12229 DO - 10.1111/bcp.12229 ID - Brauch2014 ER - TY - JOUR AU - Relling, M. V. AU - Klein, T. E. PY - 2011 DA - 2011// TI - CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network JO - Clin Pharmacol Ther VL - 89 UR - https://doi.org/10.1038/clpt.2010.279 DO - 10.1038/clpt.2010.279 ID - Relling2011 ER - TY - JOUR AU - Fernandez-Rozadilla, C. AU - Cazier, J. B. AU - Moreno, V. AU - Crous-Bou, M. AU - Guino, E. AU - Duran, G. PY - 2013 DA - 2013// TI - Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration JO - Pharmacogenomics J VL - 13 UR - https://doi.org/10.1038/tpj.2012.2 DO - 10.1038/tpj.2012.2 ID - Fernandez-Rozadilla2013 ER - TY - JOUR AU - Cao, S. AU - Wang, S. AU - Ma, H. AU - Tang, S. AU - Sun, C. AU - Dai, J. PY - 2016 DA - 2016// TI - Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy JO - Pharmacogenomics J VL - 16 UR - https://doi.org/10.1038/tpj.2015.22 DO - 10.1038/tpj.2015.22 ID - Cao2016 ER - TY - JOUR AU - Feinberg, A. P. PY - 2013 DA - 2013// TI - The epigenetic basis of common human disease JO - Trans Am Clin Climatol Assoc VL - 124 ID - Feinberg2013 ER - TY - JOUR AU - Hunter, P. PY - 2015 DA - 2015// TI - The second coming of epigenetic drugs: a more strategic and broader research framework could boost the development of new drugs to modify epigenetic factors and gene expression JO - EMBO Rep VL - 16 UR - https://doi.org/10.15252/embr.201540121 DO - 10.15252/embr.201540121 ID - Hunter2015 ER - TY - JOUR AU - Tang, J. AU - Xiong, Y. AU - Zhou, H. H. AU - Chen, X. P. PY - 2014 DA - 2014// TI - DNA methylation and personalized medicine JO - J Clin Pharm Ther VL - 39 UR - https://doi.org/10.1111/jcpt.12206 DO - 10.1111/jcpt.12206 ID - Tang2014 ER - TY - JOUR AU - Guengerich, F. P. PY - 2008 DA - 2008// TI - Cytochrome p450 and chemical toxicology JO - Chem Res Toxicol VL - 21 UR - https://doi.org/10.1021/tx700079z DO - 10.1021/tx700079z ID - Guengerich2008 ER - TY - JOUR AU - Zanger, U. M. AU - Turpeinen, M. AU - Klein, K. AU - Schwab, M. PY - 2008 DA - 2008// TI - Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation JO - Anal Bioanal Chem VL - 392 UR - https://doi.org/10.1007/s00216-008-2291-6 DO - 10.1007/s00216-008-2291-6 ID - Zanger2008 ER - TY - JOUR AU - Fisel, P. AU - Schaeffeler, E. AU - Schwab, M. PY - 2016 DA - 2016// TI - DNA methylation of ADME genes JO - Clin Pharmacol Ther VL - 99 UR - https://doi.org/10.1002/cpt.343 DO - 10.1002/cpt.343 ID - Fisel2016 ER - TY - JOUR AU - Iorio, F. AU - Knijnenburg, T. A. AU - Vis, D. J. AU - Bignell, G. R. AU - Menden, M. P. AU - Schubert, M. PY - 2016 DA - 2016// TI - A landscape of pharmacogenomic interactions in cancer JO - Cell. VL - 166 UR - https://doi.org/10.1016/j.cell.2016.06.017 DO - 10.1016/j.cell.2016.06.017 ID - Iorio2016 ER - TY - JOUR AU - Motsinger-Reif, A. A. AU - Jorgenson, E. AU - Relling, M. V. AU - Kroetz, D. L. AU - Weinshilboum, R. AU - Cox, N. J. AU - Roden, D. M. PY - 2013 DA - 2013// TI - Genome-wide association studies in pharmacogenomics: successes and lessons JO - Pharmacogenet Genom VL - 23 UR - https://doi.org/10.1097/FPC.0b013e32833d7b45 DO - 10.1097/FPC.0b013e32833d7b45 ID - Motsinger-Reif2013 ER - TY - JOUR AU - Price, M. J. AU - Carson, A. R. AU - Murray, S. S. AU - Phillips, T. AU - Janel, L. AU - Tisch, R. PY - 2012 DA - 2012// TI - First pharmacogenomic analysis using whole exome sequencing to identify novel genetic determinants of clopidogrel response variability: results of the genotype information and functional testing (GIFT) exome study JO - J Am Coll Cardiol VL - 59 UR - https://doi.org/10.1016/S0735-1097(12)60010-2 DO - 10.1016/S0735-1097(12)60010-2 ID - Price2012 ER - TY - JOUR AU - Wagle, N. AU - Grabiner, B. C. AU - Allen, E. M. AU - Hodis, E. AU - Jacobus, S. AU - Supko, J. G. AU - Stewart, M. PY - 2014 DA - 2014// TI - Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib JO - Cancer Discov VL - 4 UR - https://doi.org/10.1158/2159-8290.CD-13-0353 DO - 10.1158/2159-8290.CD-13-0353 ID - Wagle2014 ER - TY - JOUR AU - Relling, M. V. AU - Evans, W. E. PY - 2015 DA - 2015// TI - Pharmacogenomics in the clinic JO - Nature VL - 526 UR - https://doi.org/10.1038/nature15817 DO - 10.1038/nature15817 ID - Relling2015 ER - TY - JOUR AU - Vogel, C. AU - Abreu Rde, S. AU - Ko, D. AU - Le, S. Y. AU - Shapiro, B. A. AU - Burns, S. C. PY - 2010 DA - 2010// TI - Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line JO - Mol Syst Biol VL - 6 UR - https://doi.org/10.1038/msb.2010.59 DO - 10.1038/msb.2010.59 ID - Vogel2010 ER - TY - JOUR AU - Ezkurdia, I. AU - Juan, D. AU - Rodriguez, J. M. AU - Frankish, A. AU - Diekhans, M. AU - Harrow, J. PY - 2014 DA - 2014// TI - Multiple evidence strands suggest that there may be as few as 19,000 human protein-coding genes JO - Hum Mol Genet VL - 23 UR - https://doi.org/10.1093/hmg/ddu309 DO - 10.1093/hmg/ddu309 ID - Ezkurdia2014 ER - TY - JOUR AU - Jain, K. K. PY - 2004 DA - 2004// TI - Role of pharmacoproteomics in the development of personalized medicine JO - Pharmacogenomics VL - 5 UR - https://doi.org/10.1517/phgs.5.3.331.29830 DO - 10.1517/phgs.5.3.331.29830 ID - Jain2004 ER - TY - JOUR AU - Wang, Z. AU - Gerstein, M. AU - Snyder, M. PY - 2009 DA - 2009// TI - RNA-Seq: a revolutionary tool for transcriptomics JO - Nat Rev Genet VL - 10 UR - https://doi.org/10.1038/nrg2484 DO - 10.1038/nrg2484 ID - Wang2009 ER - TY - JOUR AU - Haider, S. AU - Pal, R. PY - 2013 DA - 2013// TI - Integrated analysis of transcriptomic and proteomic data JO - Curr Genom VL - 14 UR - https://doi.org/10.2174/1389202911314020003 DO - 10.2174/1389202911314020003 ID - Haider2013 ER - TY - JOUR AU - Chapal, N. AU - Molina, L. AU - Molina, F. AU - Laplanche, M. AU - Pau, B. AU - Petit, P. PY - 2004 DA - 2004// TI - Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer JO - Fundam Clin Pharmacol VL - 18 UR - https://doi.org/10.1111/j.1472-8206.2004.00258.x DO - 10.1111/j.1472-8206.2004.00258.x ID - Chapal2004 ER - TY - JOUR AU - Witzmann, F. A. AU - Grant, R. A. PY - 2003 DA - 2003// TI - Pharmacoproteomics in drug development JO - Pharmacogenomics J VL - 3 UR - https://doi.org/10.1038/sj.tpj.6500164 DO - 10.1038/sj.tpj.6500164 ID - Witzmann2003 ER - TY - JOUR AU - Meister, W. PY - 2002 DA - 2002// TI - Pharmacogenomics/pharmacoproteomics Europe JO - Pharmacogenomics VL - 3 UR - https://doi.org/10.1517/14622416.3.4.449 DO - 10.1517/14622416.3.4.449 ID - Meister2002 ER - TY - JOUR AU - Hay, M. AU - Thomas, D. W. AU - Craighead, J. L. AU - Economides, C. AU - Rosenthal, J. PY - 2014 DA - 2014// TI - Clinical development success rates for investigational drugs JO - Nat Biotechnol VL - 32 UR - https://doi.org/10.1038/nbt.2786 DO - 10.1038/nbt.2786 ID - Hay2014 ER - TY - JOUR AU - Nomura, D. K. AU - Dix, M. M. AU - Cravatt, B. F. PY - 2010 DA - 2010// TI - Activity-based protein profiling for biochemical pathway discovery in cancer JO - Nat Rev Cancer VL - 10 UR - https://doi.org/10.1038/nrc2901 DO - 10.1038/nrc2901 ID - Nomura2010 ER - TY - JOUR AU - Rix, U. AU - Superti-Furga, G. PY - 2009 DA - 2009// TI - Target profiling of small molecules by chemical proteomics JO - Nat Chem Biol VL - 5 UR - https://doi.org/10.1038/nchembio.216 DO - 10.1038/nchembio.216 ID - Rix2009 ER - TY - JOUR AU - Willems, L. I. AU - Overkleeft, H. S. AU - Kasteren, S. I. PY - 2014 DA - 2014// TI - Current developments in activity-based protein profiling JO - Bioconjug Chem VL - 25 UR - https://doi.org/10.1021/bc500208y DO - 10.1021/bc500208y ID - Willems2014 ER - TY - JOUR AU - Ong, S. E. AU - Blagoev, B. AU - Kratchmarova, I. AU - Kristensen, D. B. AU - Steen, H. AU - Pandey, A. AU - Mann, M. PY - 2002 DA - 2002// TI - Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics JO - Mol Cell Proteom VL - 1 UR - https://doi.org/10.1074/mcp.M200025-MCP200 DO - 10.1074/mcp.M200025-MCP200 ID - Ong2002 ER - TY - JOUR AU - Beck, M. AU - Schmidt, A. AU - Malmstroem, J. AU - Claassen, M. AU - Ori, A. AU - Szymborska, A. PY - 2011 DA - 2011// TI - The quantitative proteome of a human cell line JO - Mol Syst Biol VL - 7 UR - https://doi.org/10.1038/msb.2011.82 DO - 10.1038/msb.2011.82 ID - Beck2011 ER - TY - JOUR AU - Nagaraj, N. AU - Wisniewski, J. R. AU - Geiger, T. AU - Cox, J. AU - Kircher, M. AU - Kelso, J. PY - 2011 DA - 2011// TI - Deep proteome and transcriptome mapping of a human cancer cell line JO - Mol Syst Biol VL - 7 UR - https://doi.org/10.1038/msb.2011.81 DO - 10.1038/msb.2011.81 ID - Nagaraj2011 ER - TY - JOUR AU - Prieto, D. A. AU - Johann, D. J. AU - Wei, B. R. AU - Ye, X. AU - Chan, K. C. AU - Nissley, D. V. PY - 2014 DA - 2014// TI - Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens JO - Biomark Med VL - 8 UR - https://doi.org/10.2217/bmm.13.101 DO - 10.2217/bmm.13.101 ID - Prieto2014 ER - TY - JOUR AU - Klammer, M. AU - Kaminski, M. AU - Zedler, A. AU - Oppermann, F. AU - Blencke, S. AU - Marx, S. PY - 2012 DA - 2012// TI - Phosphosignature predicts dasatinib response in non-small cell lung cancer JO - Mol Cell Proteom VL - 11 UR - https://doi.org/10.1074/mcp.M111.016410 DO - 10.1074/mcp.M111.016410 ID - Klammer2012 ER - TY - JOUR AU - Kingsmore, S. F. PY - 2006 DA - 2006// TI - Multiplexed protein measurement: technologies and applications of protein and antibody arrays JO - Nat Rev Drug Discov VL - 5 UR - https://doi.org/10.1038/nrd2006 DO - 10.1038/nrd2006 ID - Kingsmore2006 ER - TY - JOUR AU - Ong, S. E. AU - Schenone, M. AU - Margolin, A. A. AU - Li, X. AU - Do, K. AU - Doud, M. K. PY - 2009 DA - 2009// TI - Identifying the proteins to which small-molecule probes and drugs bind in cells JO - Proc Natl Acad Sci U S A VL - 106 UR - https://doi.org/10.1073/pnas.0900191106 DO - 10.1073/pnas.0900191106 ID - Ong2009 ER - TY - JOUR AU - Colzani, M. AU - Noberini, R. AU - Romanenghi, M. AU - Colella, G. AU - Pasi, M. AU - Fancelli, D. PY - 2014 DA - 2014// TI - Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810 JO - Mol Cell Proteom VL - 13 UR - https://doi.org/10.1074/mcp.M113.034173 DO - 10.1074/mcp.M113.034173 ID - Colzani2014 ER - TY - JOUR AU - Kronke, J. AU - Udeshi, N. D. AU - Narla, A. AU - Grauman, P. AU - Hurst, S. N. AU - McConkey, M. PY - 2014 DA - 2014// TI - Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells JO - Science VL - 343 UR - https://doi.org/10.1126/science.1244851 DO - 10.1126/science.1244851 ID - Kronke2014 ER - TY - JOUR AU - Raj, L. AU - Ide, T. AU - Gurkar, A. U. AU - Foley, M. AU - Schenone, M. AU - Li, X. PY - 2011 DA - 2011// TI - Selective killing of cancer cells by a small molecule targeting the stress response to ROS JO - Nature VL - 475 UR - https://doi.org/10.1038/nature10167 DO - 10.1038/nature10167 ID - Raj2011 ER - TY - JOUR AU - Moellering, R. E. AU - Cravatt, B. F. PY - 2012 DA - 2012// TI - How chemoproteomics can enable drug discovery and development JO - Chem Biol VL - 19 UR - https://doi.org/10.1016/j.chembiol.2012.01.001 DO - 10.1016/j.chembiol.2012.01.001 ID - Moellering2012 ER - TY - JOUR AU - Goldstein, R. L. AU - Yang, S. N. AU - Taldone, T. AU - Chang, B. AU - Gerecitano, J. AU - Elenitoba-Johnson, K. PY - 2015 DA - 2015// TI - Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma JO - J Clin Invest VL - 125 UR - https://doi.org/10.1172/JCI80714 DO - 10.1172/JCI80714 ID - Goldstein2015 ER - TY - JOUR AU - Ning, M. M. AU - Lopez, M. AU - Sarracino, D. AU - Cao, J. AU - Karchin, M. AU - McMullin, D. PY - 2013 DA - 2013// TI - Pharmaco-proteomics opportunities for individualizing neurovascular treatment JO - Neurol Res VL - 35 UR - https://doi.org/10.1179/1743132813Y.0000000213 DO - 10.1179/1743132813Y.0000000213 ID - Ning2013 ER - TY - JOUR AU - Ohtsuki, S. AU - Hirayama, M. AU - Ito, S. AU - Uchida, Y. AU - Tachikawa, M. AU - Terasaki, T. PY - 2014 DA - 2014// TI - Quantitative targeted proteomics for understanding the blood-brain barrier: towards pharmacoproteomics JO - Expert Rev Proteom VL - 11 UR - https://doi.org/10.1586/14789450.2014.893830 DO - 10.1586/14789450.2014.893830 ID - Ohtsuki2014 ER - TY - JOUR AU - Wetmore, B. A. AU - Merrick, B. A. PY - 2004 DA - 2004// TI - Toxicoproteomics: proteomics applied to toxicology and pathology JO - Toxicol Pathol VL - 32 UR - https://doi.org/10.1080/01926230490518244 DO - 10.1080/01926230490518244 ID - Wetmore2004 ER - TY - JOUR AU - Rabilloud, T. AU - Lescuyer, P. PY - 2015 DA - 2015// TI - Proteomics in mechanistic toxicology: history, concepts, achievements, caveats, and potential JO - Proteomics VL - 15 UR - https://doi.org/10.1002/pmic.201400288 DO - 10.1002/pmic.201400288 ID - Rabilloud2015 ER - TY - JOUR AU - Summeren, A. AU - Renes, J. AU - Delft, J. H. AU - Kleinjans, J. C. AU - Mariman, E. C. PY - 2012 DA - 2012// TI - Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity JO - Toxicol In Vitro VL - 26 UR - https://doi.org/10.1016/j.tiv.2012.01.012 DO - 10.1016/j.tiv.2012.01.012 ID - Summeren2012 ER - TY - JOUR AU - Kaddurah-Daouk, R. AU - Weinshilboum, R. M. PY - 2014 DA - 2014// TI - Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology JO - Clin Pharmacol Ther VL - 95 UR - https://doi.org/10.1038/clpt.2013.217 DO - 10.1038/clpt.2013.217 ID - Kaddurah-Daouk2014 ER - TY - JOUR AU - Hao, D. AU - Sarfaraz, M. O. AU - Farshidfar, F. AU - Bebb, D. G. AU - Lee, C. Y. AU - Card, C. M. PY - 2016 DA - 2016// TI - Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment JO - Metabolomics VL - 12 UR - https://doi.org/10.1007/s11306-016-0961-5 DO - 10.1007/s11306-016-0961-5 ID - Hao2016 ER - TY - STD TI - Miolo G, Muraro E, Caruso D, Crivellari D, Ash A, Scalone S, et al. Phamacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer. Oncotarget. 2016. ID - ref68 ER - TY - STD TI - National Cancer Institute Clinical Proteomic Tumor Analysis Consortium. http://proteomics.cancer.gov/programs/cptacnetwork. Accessed 29 July 2016. UR - http://proteomics.cancer.gov/programs/cptacnetwork ID - ref69 ER - TY - JOUR AU - Mertins, P. AU - Mani, D. R. AU - Ruggles, K. V. AU - Gillette, M. A. AU - Clauser, K. R. AU - Wang, P. PY - 2016 DA - 2016// TI - Proteogenomics connects somatic mutations to signalling in breast cancer JO - Nature VL - 534 UR - https://doi.org/10.1038/nature18003 DO - 10.1038/nature18003 ID - Mertins2016 ER - TY - JOUR AU - Zhang, H. AU - Liu, T. AU - Zhang, Z. AU - Payne, S. H. AU - Zhang, B. AU - McDermott, J. E. PY - 2016 DA - 2016// TI - Integrated proteogenomic characterization of human high-grade serous ovarian cancer JO - Cell VL - 166 UR - https://doi.org/10.1016/j.cell.2016.05.069 DO - 10.1016/j.cell.2016.05.069 ID - Zhang2016 ER - TY - STD TI - Pharmacogenomics Research Network. http://www.pgrn.org. Accessed 29 July 2016. UR - http://www.pgrn.org ID - ref72 ER - TY - STD TI - Pharmacometabolomics Research Network. https://pharmacometabolomics.duhs.duke.edu/home. Accessed 29 July 2016. UR - https://pharmacometabolomics.duhs.duke.edu/home ID - ref73 ER - TY - JOUR AU - Neavin, D. AU - Kaddurah-Daouk, R. AU - Weinshilboum, R. PY - 2016 DA - 2016// TI - Pharmacometabolomics informs pharmacogenomics JO - Metabolomics VL - 12 UR - https://doi.org/10.1007/s11306-016-1066-x DO - 10.1007/s11306-016-1066-x ID - Neavin2016 ER - TY - JOUR AU - Kaddurah-Daouk, R. AU - Weinshilboum, R. PY - 2015 DA - 2015// TI - Metabolomic signatures for drug response phenotypes: pharmacometabolomics enables precision medicine JO - Clin Pharmacol Ther VL - 98 UR - https://doi.org/10.1002/cpt.134 DO - 10.1002/cpt.134 ID - Kaddurah-Daouk2015 ER - TY - STD TI - U.S. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm (2016). Accessed 29 July 2016. UR - http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm ID - ref76 ER - TY - JOUR AU - Tutton, R. PY - 2014 DA - 2014// TI - Pharmacogenomic biomarkers in drug labels: what do they tell us? JO - Pharmacogenomics VL - 15 UR - https://doi.org/10.2217/pgs.13.198 DO - 10.2217/pgs.13.198 ID - Tutton2014 ER - TY - STD TI - U.S. Food and Drug Administration. Nucleic acid based tests. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm330711.htm. Accessed 29 July 2016. UR - http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm330711.htm ID - ref78 ER - TY - STD TI - Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories: Framework for regulatory oversight of laboratory developed tests (LDTs). U.S. Department of Health and Human Services Food and Drug Administration, Docket no. FDA-2011-D-0360; 2014. ID - ref79 ER - TY - JOUR AU - Levy, K. D. AU - Pratt, V. M. AU - Skaar, T. C. AU - Vance, G. H. AU - Flockhart, D. A. PY - 2015 DA - 2015// TI - FDA’s draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing JO - J Clin Pharmacol VL - 55 UR - https://doi.org/10.1002/jcph.492 DO - 10.1002/jcph.492 ID - Levy2015 ER - TY - JOUR AU - Fuzery, A. K. AU - Levin, J. AU - Chan, M. M. AU - Chan, D. W. PY - 2013 DA - 2013// TI - Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges JO - Clin Proteom VL - 10 UR - https://doi.org/10.1186/1559-0275-10-13 DO - 10.1186/1559-0275-10-13 ID - Fuzery2013 ER - TY - JOUR AU - Tabb, D. L. AU - Vega-Montoto, L. AU - Rudnick, P. A. AU - Variyath, A. M. AU - Ham, A. L. AU - Bunk, D. M. PY - 2010 DA - 2010// TI - Repeatability and reproducibility in proteomic identifications by liquid chromatography—tandem mass spectrometry JO - J Proteome Res VL - 9 UR - https://doi.org/10.1021/pr9006365 DO - 10.1021/pr9006365 ID - Tabb2010 ER - TY - JOUR AU - Addona, T. A. AU - Abbatiello, S. E. AU - Schilling, B. AU - Skates, S. J. AU - Mani, D. R. AU - Bunk, D. M. PY - 2009 DA - 2009// TI - Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma JO - Nat Biotechnol VL - 27 UR - https://doi.org/10.1038/nbt.1546 DO - 10.1038/nbt.1546 ID - Addona2009 ER - TY - JOUR AU - Marioni, J. C. AU - Mason, C. E. AU - Mane, S. M. AU - Stephens, M. AU - Gilad, Y. PY - 2008 DA - 2008// TI - RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays JO - Genome Res VL - 18 UR - https://doi.org/10.1101/gr.079558.108 DO - 10.1101/gr.079558.108 ID - Marioni2008 ER - TY - STD TI - NIH Cancer Genome Atlas. http://cancergenome.nih.gov. Accessed 8 Sept 2016. UR - http://cancergenome.nih.gov ID - ref85 ER - TY - STD TI - The International Cancer Genome Consortium. http://www.icgc.org. Accessed 8 Sept 2016. UR - http://www.icgc.org ID - ref86 ER - TY - JOUR AU - Ferreira, C. R. AU - Yannell, K. E. AU - Jarmusch, A. K. AU - Pirro, V. AU - Ouyang, Z. AU - Cooks, R. G. PY - 2016 DA - 2016// TI - Ambient ionization mass spectrometry for point-of-care diagnostics and other clinical measurements JO - Clin Chem VL - 62 UR - https://doi.org/10.1373/clinchem.2014.237164 DO - 10.1373/clinchem.2014.237164 ID - Ferreira2016 ER -